Nivolumab (NIVO) +/- ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.-MedSci.cn

Nivolumab (NIVO) +/- ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Overman, MJ; Lenz, HJ; Andre, T; Aglietta, M; Wong, MK; Luppi, G; Van Cutsem, E; McDermott, RS; Hendlisz, A; Cardin, DB; Morse, M; Neyns, B; Hill, AG; Limon, ML; Garcia-Alfonso, P; Krishnamurthy, A; Chen, F; Abdullaev, S; Soleymani, S; Lonardi, S

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务